| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| José Ángel García-Pedraza, Mónica García, María Luisa Martín, Nélida Eleno, Asunción Morá. Chronic Sarpogrelate Treatment Reveals 5-HT7 Receptor in the Serotonergic Inhibition of the Rat Vagal Bradycardia. Journal of cardiovascular pharmacology. vol 69. issue 1. 2017-11-27. PMID:27676327. |
the iv administration of 5-ht (10-200 μg/kg) dose dependently decreased the vagally induced bradycardia, and agonists 5-ct (5-ht1/7), 8-oh-dpat (5-ht1a), or as-19 (5-ht7) (50 μg/kg each) mimicked the 5-ht-induced inhibitory effect. |
2017-11-27 |
2023-08-13 |
rat |
| Andrea de Bartolomeis, Andrea Fagiolini, Giuseppe Main. [Vortioxetine in the treatment of major depression]. Rivista di psichiatria. vol 51. issue 6. 2017-11-20. PMID:27996982. |
vortioxetine is a multi-modal antidepressant that functions both as serotonin transporter (sert) inhibitor and as 5-ht3, 5-ht7 and 5-ht1d receptors antagonist, 5-ht1a receptor agonist and 5-ht1b receptor partial agonist. |
2017-11-20 |
2023-08-13 |
Not clear |
| Annina Huser, Melanie Eschment, Nazli Güllü, Katharina A N Collins, Kathrin Böpple, Lyubov Pankevych, Emilia Rolsing, Andreas S Thu. Anatomy and behavioral function of serotonin receptors in Drosophila melanogaster larvae. PloS one. vol 12. issue 8. 2017-10-10. PMID:28777821. |
our data suggest that 5-ht1a, 5-ht1b, and 5-ht7 are dispensable for larval naïve olfactory and gustatory choice behaviors as well as for appetitive and aversive associative olfactory learning and memory. |
2017-10-10 |
2023-08-13 |
drosophila_melanogaster |
| Edward Ofori, Xue Y Zhu, Jagan R Etukala, Kwakye Peprah, Kamanski R Jordan, Adia A Adkins, Barbara A Bricker, Hye J Kang, Xi-Ping Huang, Bryan L Roth, Seth Y Ablordeppe. Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands. Bioorganic & medicinal chemistry. vol 24. issue 16. 2017-08-02. PMID:27312422. |
5-ht1a and 5-ht7 receptors have been at the center of discussions recently due in part to their major role in the etiology of major central nervous system diseases such as depression, sleep disorders, and schizophrenia. |
2017-08-02 |
2023-08-13 |
Not clear |
| Sebastiano Intagliata, Maria N Modica, Valeria Pittalà, Loredana Salerno, Maria A Siracusa, Alfredo Cagnotto, Mario Salmona, Giuseppe Rome. Design and synthesis of new homo and hetero bis-piperazinyl-1-propanone derivatives as 5-HT7R selective ligands over 5-HT1AR. Bioorganic & medicinal chemistry letters. vol 26. issue 16. 2017-07-26. PMID:27396505. |
these newly synthesized compounds possess a 4-arylpiperazine linked through an acyl spacer to another substituted piperazine system and were tested for their binding properties on human cloned 5-ht1a and 5-ht7 serotonin receptors. |
2017-07-26 |
2023-08-13 |
human |
| Laura Orsolini, Carmine Tomasetti, Alessandro Valchera, Felice Iasevoli, Elisabetta Filomena Buonaguro, Federica Vellante, Michele Fornaro, Annastasia Fiengo, Monica Mazza, Roberta Vecchiotti, Giampaolo Perna, Andrea de Bartolomeis, Giovanni Martinotti, Massimo Di Giannantonio, Domenico De Berardi. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert review of neurotherapeutics. vol 16. issue 5. 2017-06-27. PMID:27050932. |
vortioxetine (vrx) is a multimodal antidepressant with a unique mechanism of action, by acting as 5-ht3a, 5-ht1d and 5-ht7 receptor antagonist, partial agonist at the 5-ht1a and 5-ht1b receptors and inhibitor at the 5-ht transporter. |
2017-06-27 |
2023-08-13 |
Not clear |
| Enza Lacivita, Sabina Podlewska, Luisa Speranza, Mauro Niso, Grzegorz Satała, Roberto Perrone, Carla Perrone-Capano, Andrzej J Bojarski, Marcello Leopold. Structural modifications of the serotonin 5-HT7 receptor agonist N-(4-cyanophenylmethyl)-4-(2-biphenyl)-1-piperazinehexanamide (LP-211) to improve in vitro microsomal stability: A case study. European journal of medicinal chemistry. vol 120. 2017-02-13. PMID:27318552. |
the majority of the synthesized compounds maintained high affinity for 5-ht7 receptors and showed selectivity towards 5-ht6 and dopamine d2 receptors and different selectivity for 5-ht1a and α1 adrenergic receptors. |
2017-02-13 |
2023-08-13 |
mouse |
| Gennady N Smagin, Dekun Song, David P Budac, Jessica A Waller, Yan Li, Alan L Pehrson, Connie Sánche. Histamine may contribute to vortioxetine's procognitive effects; possibly through an orexigenic mechanism. Progress in neuro-psychopharmacology & biological psychiatry. vol 68. 2017-01-02. PMID:26945513. |
vortioxetine is a novel multimodal antidepressant that acts as a serotonin (5-ht)3, 5-ht7, and 5-ht1d receptor antagonist; 5-ht1b receptor partial agonist; 5-ht1a receptor agonist; and 5-ht transporter inhibitor in vitro. |
2017-01-02 |
2023-08-13 |
rat |
| Jessica A Waller, Fenghua Chen, Connie Sánche. Vortioxetine promotes maturation of dendritic spines in vitro: A comparative study in hippocampal cultures. Neuropharmacology. vol 103. 2016-12-13. PMID:26702943. |
the multimodal-acting antidepressant vortioxetine is an antagonist at 5-ht3, 5-ht7, and 5-ht1d receptors, a partial agonist at 5-ht1b receptors, an agonist at 5-ht1a receptors, and an inhibitor of the serotonin (5-ht) transporter (sert) and has pro-cognitive properties. |
2016-12-13 |
2023-08-13 |
Not clear |
| D J David, L Tritschler, J-P Guilloux, A M Gardier, C Sanchez, R Gaillar. [Pharmacological properties of vortioxetine and its pre-clinical consequences]. L'Encephale. vol 42. issue 1 Suppl 1. 2016-12-13. PMID:26879252. |
compared to the ssris, vortioxetine is defined as a multimodal antidepressant drug since it is not only a serotonin reuptake inhibitor, but also a 5-ht1d, 5-ht3, 5-ht7 receptor antagonist, 5-ht1b receptor partial agonist and 5-ht1a receptor agonist. |
2016-12-13 |
2023-08-13 |
Not clear |
| Katarzyna Kucwaj-Brysz, Dawid Warszycki, Sabina Podlewska, Jagna Witek, Karolina Witek, Andrea González Izquierdo, Grzegorz Satała, María I Loza, Annamaria Lubelska, Gniewomir Latacz, Andrzej J Bojarski, Marián Castro, Katarzyna Kieć-Kononowicz, Jadwiga Handzli. Rational design in search for 5-phenylhydantoin selective 5-HT7R antagonists. Molecular modeling, synthesis and biological evaluation. European journal of medicinal chemistry. vol 112. 2016-11-07. PMID:26900658. |
a series of novel arylpiperazine 5-(4-fluorophenyl)-5-methylhydantoins with 2-hydroxypropyl linker (2-15) was synthesized and evaluated on their affinity towards serotonin 5-ht7 receptor (5-ht7r) in comparison to other closely related gpcrs: serotonin 5-ht1a, and dopamine d2 receptors. |
2016-11-07 |
2023-08-13 |
human |
| Stephan Köhler, Katharina Cierpinsky, Golo Kronenberg, Mazda Adl. The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. Journal of psychopharmacology (Oxford, England). vol 30. issue 1. 2016-09-26. PMID:26464458. |
against this background, we feature the novel antidepressants vortioxetine, vilazodone and milnacipran/levomilnacipran with regard to their serotonin receptor targets such as the 5-ht1a, 5-ht3 and 5-ht7 which may account for their specific effects on certain symptoms of depression (e.g. |
2016-09-26 |
2023-08-13 |
Not clear |
| Tiberiu Loredan Stan, Vasco Cabral Sousa, Xiaoqun Zhang, Michiko Ono, Per Svenningsso. Lurasidone and fluoxetine reduce novelty-induced hypophagia and NMDA receptor subunit and PSD-95 expression in mouse brain. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 10. 2016-07-12. PMID:26256011. |
lurasidone acts as a high affinity antagonist at multiple monoamine receptors, particularly 5-ht2a, 5-ht7, d2 and α2 receptors, and as a partial agonist at 5-ht1a receptors. |
2016-07-12 |
2023-08-13 |
mouse |
| Steven C Leiser, Deborah Iglesias-Bregna, Ligia Westrich, Alan L Pehrson, Connie Sanche. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism. Journal of psychopharmacology (Oxford, England). vol 29. issue 10. 2016-06-23. PMID:26174134. |
vortioxetine, a multimodal antidepressant acting through serotonin (5-ht) transporter (sert) inhibition, 5-ht3, 5-ht7 and 5-ht1d receptor antagonism, 5-ht1b receptor partial agonism, and 5-ht1a receptor agonism, had fewer incidences of sleep-related adverse events reported in depressed patients. |
2016-06-23 |
2023-08-13 |
human |
| Agnieszka Gunia-Krzyzak, Karolina Pytka, Karolina Słoczyńska, Anna M Waszkielewicz, Grzegorz Satała, Andrzej J Bojarski, Jacek Sapa, Barbara Filipek, Marek Cegła, Elzbieta Pekala, Henryk Maron. PRELIMINARY EVALUATION OF CENTRAL NERVOUS SYSTEM ACTIVITY OF (E)-N-2-METHYL-3-PHENYLPROP-2-ENYL ((E)-N- α-METHYLCINNAMYL) DERIVATIVES OF SELECTED AMINOALKANOLS. Acta poloniae pharmaceutica. vol 73. issue 2. 2016-06-20. PMID:27180427. |
to identify possible mechanism of action, we evaluated serotonin receptors (5-ht1a, 5-ht6 and 5-ht7) binding affinities of the compounds but none of them proved to bind to any of tested receptors. |
2016-06-20 |
2023-08-13 |
mouse |
| Karolina Pytka, Anna Partyka, Magdalena Jastrzębska-Więsek, Agata Siwek, Monika Głuch-Lutwin, Barbara Mordyl, Grzegorz Kazek, Anna Rapacz, Adrian Olczyk, Adam Gałuszka, Marian Błachuta, Anna Waszkielewicz, Henryk Marona, Jacek Sapa, Barbara Filipek, Anna Wesołowsk. Antidepressant- and Anxiolytic-Like Effects of New Dual 5-HT₁A and 5-HT₇ Antagonists in Animal Models. PloS one. vol 10. issue 11. 2016-06-13. PMID:26554929. |
our results indicate that hbk-14 and hbk-15 possess high or moderate affinity for serotonergic 5-ht2, adrenergic α1, and dopaminergic d2 receptors as well as being full 5-ht1a and 5-ht7 receptor antagonists. |
2016-06-13 |
2023-08-13 |
mouse |
| Kazumasa Matsumoto-Miyai, Masaru Yoshizumi, Masahito Kawatan. Regulatory Effects of 5-Hydroxytryptamine Receptors on Voiding Function. Advances in therapy. vol 32 Suppl 1. 2016-05-25. PMID:26391372. |
5-ht2a, 5-ht2c, 5-ht3, 5-ht4, and 5-ht7 subtypes facilitate the neurogenic contraction of the detrusor by enhancing cholinergic or purinergic transmission, whereas 5-ht1a receptors might inhibit the release of acetylcholine in the detrusor. |
2016-05-25 |
2023-08-13 |
Not clear |
| José-Ángel García-Pedraza, Mónica García, María-Luisa Martín, Asunción Morá. 5-HT1D receptor inhibits renal sympathetic neurotransmission by nitric oxide pathway in anesthetized rats. Vascular pharmacology. vol 72. 2016-05-19. PMID:26003124. |
bolus of agonists α-methyl-5-ht (5-ht2), 1-pbg (5-ht3), cisapride (5-ht4), as-19 (5-ht7), cgs-12066b (5-ht1b) or 8-oh-dpat (5-ht1a) (0.0125μg/kg each). |
2016-05-19 |
2023-08-13 |
rat |
| Clinton E Canal, Daniel E Felsing, Yue Liu, Wanying Zhu, JodiAnne T Wood, Charles K Perry, Rajender Vemula, Raymond G Boot. An Orally Active Phenylaminotetralin-Chemotype Serotonin 5-HT7 and 5-HT1A Receptor Partial Agonist that Corrects Motor Stereotypy in Mouse Models. ACS chemical neuroscience. vol 6. issue 7. 2016-04-19. PMID:26011730. |
an orally active phenylaminotetralin-chemotype serotonin 5-ht7 and 5-ht1a receptor partial agonist that corrects motor stereotypy in mouse models. |
2016-04-19 |
2023-08-13 |
mouse |
| Clinton E Canal, Daniel E Felsing, Yue Liu, Wanying Zhu, JodiAnne T Wood, Charles K Perry, Rajender Vemula, Raymond G Boot. An Orally Active Phenylaminotetralin-Chemotype Serotonin 5-HT7 and 5-HT1A Receptor Partial Agonist that Corrects Motor Stereotypy in Mouse Models. ACS chemical neuroscience. vol 6. issue 7. 2016-04-19. PMID:26011730. |
for example, preclinical studies indicate that 5-ht7 receptor activation corrects deficits in mouse models of fragile x and rett syndromes, and clinical trials for autism are underway with buspirone, a 5-ht1a partial agonist with relevant affinity at 5-ht7 receptors. |
2016-04-19 |
2023-08-13 |
mouse |